13th annual report the preeminent source for medical benefit drug trend

Nov. 29, 2024 - ustekinumab-kfce (Yesintek) The FDA has approved Biocon’s Yesintek as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is indicated for all...

The Spring 2026 Prime Therapeutics Report delivers a forward-looking view of specialty and rare disease management—highlighting breakthrough approvals, expanding pipelines and the payer strategies...

Managed Healthcare Executive

Real-World 3-Year Cost Impact Assessment of Glucagon-Like Peptide-1 Agonists to Treat Obesity Among Commercially Insured Members without Diabetes This study earned a silver award from AMCP. It...

More than 300 pharma representatives attended this annual gathering to learn more about what Prime/MRx has to offer

*select countries included adolescents 12 years and older weighing 30 kg or more Autoimmune/immunology Proposed indications Treatment of Steroid-Refractory Acute Graft vs. Host Disease (SR-aGVHD) –...

Biobetters are just a nickname; they’re based on existing biologics but with a few key differences